These cells have also been identified as promising candidates for CD8+ T cell‐based immunotherapies, with evidence suggesting their potential to mediate the eradication of autologous tumor cells in patients with DLBCL. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.